1www.wholesaleinvestor.com.au

ASX-listed payments provider focusedon emerging markets (19)

Emerging biotech with unique vaccine technology (10)

Renewable Energy company with scalable tidal technology (13)

Consumer health company withhigh potential brands (12)

Technology solution provider for self managed superannuation (21)

Investment Opportunities for Wholesale, Sophisticated & High Net Worth Investors

De

ce

mb

er

20

11

Renewable Energy company with scalable wave technology (16)

Contents

DECEMBER 2011Wholesale Investor Magazine is published by:

Wholesale Investor Pty Ltd

ACN 131 512 715

Managing Director - Steve Torso

Publisher - Reuben Buchanan

Editor - Lachlan Colquhoun

General Manager - Kimber Rothwell

Senior Account Managers:- Daniel Coombes- Jason Ballo

Directors

Reuben Buchanan – Executive DirectorDomenic Carosa – Non Executive Director

Advisory board Tim Trumper

Sydney:

Address - Suite 204, 66 King St. SydneyPhone - 1300 597 595Web - www.wholesaleinvestor.com.au

Editorial Enquiries

editorial@wholesaleinvestor.com.au

Advertising Enquiries

advertising@wholesaleinvestor.com.au

Listing Enquiries

capital@wholesaleinvestor.com.au

1300 597 595

Subscription Enquiries

subscribe@wholesaleinvestor.com.au

Design - Bubblefish Designwww.bubblefish.com.au

Printer - GEON Groupwww.geongroup.com

Distribution - GEON Groupwww.geongroup.com

Disclaimer

This Publication contains prominent statements

appropriate for the particular medium by which

the Publication is made to the effect that:

(A) the information contained in the Publication

about the proposed business opportunity

and the securities or scheme interests is not

intended to be the only information on which

the investment decision is made and is not a

substitute for a disclosure document, Product

Disclosure Statement or any oth er notice that

may be required under the Act, as that Act may

apply to the investment. Detailed information may

be needed to make an investment decision, for

example: financial statements; a business plan;

information about ownership of intellectual or

industrial property; or expert opinions including

valuations or auditors’ reports; and

(B) a prospective investor is strongly advised

to take appropriate professional advice before

accepting an offer for issue or sale of any

securities or scheme interests;

For more information, please visit our website

www.wholesaleinvestor.com.au or email

info@wholesaleinvestor.com.au

Editorial

3 Letter from the Managing Director

4 PwC survey of business intentions

5 Consensus Awards

29 Company Updates

30 Upcoming Events

Opportunities

6 Mesynthes Ltd

7 Benitec

8 Jubilent Health

9 Global Kinetics Corporation

10 BioDiem Ltd

11 Xenexus Pharmaceuticals

12 Cynergy Health

13 Elemental Energy

14 EcoQuest

16 BioPower

17 Eastern Harmony New Zealand

18 Exa Web Solutions

19 Mint Wireless

20 Equiome

21 Investment Administration

22 BlackWall Property Fund

23 Bizpanel

24 TRAC Financial

25 Folkestone

26 Bullion Capital

27 Hannan Logistics

28 Flinders Exploration

31 Listings Page

Letter from the Managing Director

Next Year looks like being a significant year in the evolution of Wholesale Investor as the leading distribution channel to investors for private, pre IPO, IPO and small cap listed entities.Here in Australasia, we are blessed with a strong spirit of innovation and entrepreneurship which means that at all levels, in all sectors, there are visionary business founders working on what they think is the next big idea.

And the evidence, both anecdotally and more empirically through our Wholesale Investor Sentiment Survey, shows that sophisticated investors are as willing as they have ever been to listen to the pitch from new companies.

Biotech and cleantech companies have continued to be the flavour of the year for 2011, and that is likely to continue into 2012. The passage of the Government’s carbon tax legislation and the agreement by APEC leaders to cut tariffs for cleantech exports will doubtlessly have a positive impact on that sector, while the momentum for health and biotech remains undiminished.

The mining boom remains a strong feature of Australia’s economic landscape, and at Wholesale Investor we have continued to bring a pipeline of exciting resource-based opportunities to our subscribers. All the evidence shows that the resources boom has some time yet to run, so we look forward to more mining opportunities in 2012.

Next year looks like being a significant year in the evolution of Wholesale Investor as the leading distribution channel to investors for growth companies and Small Cap Listed companies. We will continue to do more of what we do well: our events linking companies and investors, our partnerships with the likes of PwC and our print and online communication platforms.

Already, we have plans to significantly improve our digital offering and get closer to what the smart money is thinking through a new and better version of our investor survey, which we think will become a closely watched benchmark in the market.

We will further develop our channel partner program giving corporate advisory and finance, private equity and venture capital firms the opportunity to use our unique distribution platform for the benefit of their clients.

For now, its time to sign off on 2011 from me and the Wholesale Investor team, and thank all our stakeholders – investors and entrepreneurs alike – for engaging with us this year. We look forward to seeing more of you in 2012, and making the coming year a major success for us all.

Regards,

Steve Torso - Managing Director, Wholesale Investor

3

4

Medium-term profit outlooks are also much more bullish than sales

expectations with 80 per cent of the segment expecting growth at 11.6 per

cent. This is particularly pronounced in the ASX segment (90 per cent are

looking at profit growth) and weakest amongst private companies (68.8 per

cent).

The top three impediments to achieving growth targets are global economic

conditions, lack of consumer confidence and government leadership. Global

conditions are an especially high barrier for multinationals, whereas consumer

confidence issues lead for private businesses and the ASX segment.

Credit: This story appears in PwC’s Spring 2011 Radar publication, which focuses on the key trends and issues affecting ASX listed companies, inbound multinationals, and large private businesses. To download a copy of Radar please visit pwc.com.au/radar or download the Radar iPad App from the Apple Store. Search PwC Australia – Private Clients.

While the short-term outlook is conservative and coloured by uncertainty, the

medium-term outlook is considerably more optimistic. Most businesses are

cutting costs where they can, but some are seeking out opportunities and

reaping the rewards.

Businesses across Australia are telling us their three key competitive drivers

are margin compression, talent availability and pricing. To some extent, these

are not new concerns, but uncertainty around the global and Australian

economies, including the impact of the carbon tax, seems to be prompting

many businesses to adopt a ‘wait and see’ approach. The much-vaunted

two-speed economy does appear to be real, with marked differences in plans

around investment, expansion and hiring for the mining and resources sector –

for most of these companies, it’s full-steam ahead.

In the meantime, those that can are endeavouring to better manage their costs.

This is where the forecast profit growth across the board is likely to come

from for most businesses, rather than an increase in revenue. The challenge

for businesses is to ensure they are not cutting fat too close to the bone, and

they could find themselves in a less-than-ideal situation when the inevitable

upswing arrives.

Given, however, that the top three impediments to achieving growth targets are

cited as global economic conditions, lack of consumer confidence and lack of

clear leadership from government, and with most businesses predicting flat or

very low growth for the Australian economy over the next 12 months, perhaps

they are wise to “batten down the hatches” and get ready for what may indeed

be a bumpy ride – for at least the next 12 months.

Over the next three years, the outlook is much more buoyant, with not one

business surveyed forecasting negative profit growth. It appears they are

anticipating that the uncertainties around global economic conditions and the

carbon tax, seen almost universally as likely to impact negatively on business,

will be largely resolved, and we can all get back to the task at hand.

Profit growth has been much stronger than revenue with nearly 80 per cent of

enterprises reporting either static (26.9 per cent) or increased (51.8 per cent)

revenues in 2011 – a reflection of the increased focus on cost containment

and margin management. This was strongest amongst ASX-listed companies,

and weakest among large private companies, with nearly one third (31.3 per

cent) recording a drop compared to 12 months ago. Profit expectations are

considerably stronger than sales for 2012 – 72.5 per cent are expecting growth

at an average rate of 8.1 per cent; this is strongest amongst ASX companies

and multinational corporations in Australia; again, weakest among private

companies.

Business growth and strategy

5

The 2011 Consensus Software Awards were presented at the Amora Jamison

Hotel in Sydney on Wednesday 9th November by The Hon Malcolm Turnbull,

Shadow Minister for Communuications & Broadband.

The Awards identify the most innovative software in Australia and New Zealand.

They are endorsed and supported by Austrade, NZ Trade & Enterprise, Australian

Computer Society and New Zealand Computer Society. Program Partners are

Clifton’s, TiE and Alinement. Wholesale Investor is the Media Partner.

2011 Winners

GeoOPwww.geoop.com

from GeoOP Limited (NZ)

GeoOP (Geo Operations) is a job dispatch, mobile workforce management and

GPS tracking system that leverages Cloud computing, geo-location based

mobile applications, SMS and the iOS / Android platforms. In a nutshell, it tells

your field staff where to go and what to do via their mobile phone. It is presently

being used by paying customers in NZ, Australia, UK, South Africa, Canada and

the USA in these industries: Freight, IT, Audio Visual, Sign Writing, Landscaping,

Trades, Maintenance, Health care, Pest control and Security. GeoOP was

deployed after the Christchurch earthquakes, enabling the 15,000 volunteers of

the Student Volunteer Army (SVA) to coordinate the huge amount of work that

was required to assist people in need.

2011 CONSENSUS SOFTWARE AWARDSGuestPoint® www.centiumsoftware.com

from Centium Software (QLD)

In 2011, Centium released, GuestPoint® - an accommodation management

system purpose-built for small to mid-sized regional properties. GuestPoint®

is the first of a new generation of software in this space that gives small

operators a suite of powerful tools to enable them to compete in the online

world without detailed knowledge and experience. GuestPoint® integrates

sophisticated web booking technologies into the real-world reservation

environment, simplifying the management of online reservations, web

booking channels, dynamic rate and real-time online inventory management.

GuestPoint® is delivered with WebPoint®, an online booking link added to

property web sites and includes search engine optimization to enhance web

presence.

riskware®

www.riskware.com.au

from PAN Software (VIC)

riskware® is a web-based application complying with the new international

risk management standard (ISO 31000:2009) and extending it by integrating

10 modules which all “feed-off” each other providing a holistic view for

organisational risk. Whether an enterprise manages financial, information

systems, people, resources, government policies, etc., riskware® can be

utilised to manage organisational risk. riskware® can potentially replace up to

10 different applications with 1 web-enabled solution, which collectively we call

Enterprise Risk Intelligence (ERI) software.

The Manufacturing Simulation www.abw.org.au

from Australian Business Week Limited (NSW)

The Manufacturing Simulation is aimed at students in years 10 and 11 in

high school and is intended to take them through the process of running a

business making sporting goods. Participating students form into teams of ten

supported by both a teacher mentor and a business mentor recruited from the

local business community. Each team is responsible for the election of a Chief

Executive Officer and the allocation of team members to each of the Marketing,

Operations and Finance positions. Every position is important for making the

decisions related to that role and for working cooperatively with the rest of the

team. The key to success is to encourage the students to work together as a

team! The companies sell in three markets; local (home market), national (other

areas in the home country) and international, (the export market).

6

Executive SummaryMesynthes is a soft-tissue reconstruction company using its proprietary Endoform technology

to develop regenerative tissue substitutes for reconstructive surgery and wound care.

These markets represent an opportunity in excess of US$1B.

Mesynthes gained marketing clearance from the United States FDA in January 2010 for

Endoform™ Dermal Template for acute and chronic wounds. In March 2011, the company

secured a North American marketing and distribution agreement with a major healthcare

multinational for their first Endoform based product and they have also entered into

a development agreement with another major wound care multinational. A specialised

manufacturing facility operating under a quality management system was commissioned

in early 2011.

Competitive Advantages• Compared to established market offerings Endoform™ is a shelf-stable tissue substitute with:

• Authentic structure, signals and substrates of the native extracellular matrix

• Quantifiably superior blood vessel in-growth

• Complete remodelling and replacement by the patients’ own tissue over time

• Clinical outcomes in diabetic and venous ulcers studies which are very encouraging (n>50)

• Excellent strength and handling characteristics

• Three year shelf life at ambient temperatures

• Pipeline developments for implantable products and potential for delivery of cells,

antimicrobials and bio-actives

Key Investment Highlights• Sustainable competitive advantage, in large growing markets

• Platform technology supports development of multiple high-value products. The first product

will launch in 2011 and one further product is expected to launch in 2012

• Technology and regulatory risks addressed

• World leading team with experienced Board, Advisory Board and Investors - Management

team have in excess of 60 years of combined experience in the life sciences sector.

The Board of Directors has extensive international commercial experience and the Clinical

Advisory Board is comprised of leading United States based clinicians and academics.

Mesynthes has been backed by New Zealand’s premier early-stage investors

• Secured partnerships with multinational companies

• Demonstrated capability to achieve significant results with limited resources. To date,

the company has raised $4M from private investors

Board & Management:

Brian Ward - CEO BVSc MRCVS MBA(dist) Brian Ward has held senior roles in life science companies over the last 20 years.

Nancy Yopp - Director OperationsBS, MBANancy Yopp has over 25 years of technical, manufacturing and operations experience in the US medical device industry.

Barnaby May - Director Research PhDBarnaby May has an extensive research and development experience in academia and industry.

Phil McCaw - ChairBBSPhil McCaw is a qualified chartered accountant and has served on the Boards of numerous early stage companies and is an active angel investor.

Corporate StructureMesynthes is a New Zealand registered private company.

Exit StrategyA number of exit options exist for investors over the next 2-5 years including:Acquisition by a major medical device company, a merger with an established company with complimentary technology or marketing channels, or an IPO on a suitable public exchange.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Mesynthes Ltd.

BIO TECH

Mesynthes Ltd

Medical Device

2007

Early stage

Wellington, New Zealand

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

7

Benitec Limited (ASX:BLT)

Biotechnology-therapeutics

1997

Early Stage

Sydney

Company Name

Sector

Year Established

Business Stage

Location

BIO TECH

Executive Summary Benitec Limited is a publicly listed (ASX:BLT) biotechnology company developing novel

human therapies based on a transformational gene silencing technology, DNA-directed RNA

interference (ddRNAi). Benitec holds the predominant patent position in the use of ddRNAi

for human therapeutics, with an exclusive, irrevocable, world-wide license to CSIRO’s patent

estate by generating double stranded RNA inside a cell from a DNA construct. Benitec

collaborates with groups globally to develop novel therapeutics for chronic life threatening

diseases and disorders, particularly in cancer and infectious disease. Benitec’s current projects

are directed to using gene silencing in lung cancer, intractable cancer-associated pain, and

hepatitis B infection.

Competitive Advantages• Cancer-associated neuropathic pain. The program is aimed at developing a ddRNAi-based

therapeutic to silence genes in the spinal cord involved in mediating intractable pain.

• The non-small cell lung cancer program, in collaboration with the University of New South

Wales. Researchers at UNSW have shown that using ddRNAi to silence the beta III tubulin

gene can significantly overcome the resistance of lung cancer cells to chemotherapy drugs.

These programs are fully Benitec funded programs. It is anticipated that these programs will

enter Phase I clinical trials in 2012.

• The hepatitis B program is developing a ddRNAi-based therapeutic targeting a key HBV gene.

Partnered with Biomics Biotechnologies Co, Ltd in China.

Key Milestones & Investment Highlights• Exclusive irrevocable worldwide rights to a platform technology with huge market potential in

human therapy: ability to permanently silence any gene associated with a disease or

condition

• Dominant global position with robust intellectual property, including successful

re-examination in all major jurisdictions worldwide. Over 30 patents granted internationally.

• Broad portfolio of targeted therapeutics – neuropathic pain, lung cancer and hepatitis B

• Building value through licensing of therapeutics and technology

• Financially strengthened by recent successful $8M funding via a renounceable rights issue

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search forBenitec.

Board & Management:

Peter French - CEOBSc, MSC, MBA, PhDCell and molecular biologist. Principal Scientist - Centre for Immunology, St Vincent’s Hospital; Founder of Cryosite (CTE); Ex-President ANZSCDBI.

Peter Francis - Non-Executive ChairmanLLB Grad Dip (Intellectual Property)Partner at Francis Abourizk Lightowlers (FAL), a firm of commercial and technology. He is a legal specialist in the areas of intellectual property and licensing.

Mel Bridges - Non-Executive DirectorBAppSc FAICDMore than 30 years experience in the global biotechnology and healthcare industry. Chairman of Alchemia Limited, Impedimed Limited and Leaf Energy Limited. He also co-founded the listed company Panbio Ltd. Tissue Therapies Limited. The Queensland Entrepreneur of the Year in 2004.

John Chiplin – Non-Executive DirectorPh.DFormer CEO of Arana Therapeutics (acquired by Cephalon). Former head of the $300M ITI Life Sciences investment fund in the UK. Owns Newstar Ventures Ltd.

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX :BLT

15,061,145

$0.0160

0.0450

0.0140

Share Information As at 9 December 2011

Jul 2011 Aug 2011 Sep 2011 Oct 2011 Nov 2011 Dec 2011

ASX:BLT 6 month price chart

0.03

0.03

0.02

0.02

40

30

20

10

0

Volume (mil/1d)

8

BIO TECH

Jubilent Health Aust Limited

OTC medicines

4

Market ready

Australia

5 mil equity to scale

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Executive Summary Jubilent Health Aust. Limited is poises for rapid growth and is inviting investors onboard in

order to fund the scaling up of proven existing business and expansion of the unique product

range to sell into existing and new pharmacy customers and begin the global expansion of it’s

brands.

Jubilent Health Aust. Limited, an Australian Pharmaceutical company, has unique patented

technologies resulting in formulae’s and API’s (Active Pharmaceutical Ingredients) which will

change the way many medical conditions and diseases are treated. Conditions like Obesity,

Diabetes, High Cholesterol, and even male infertility will be treated by medicines produced by

Jubilent, by targeting fundamental cellular mechanisms to reverse symptoms at their origins

and so reverse diagnosis.

Jubilent Health Aust. Limited will continue to manufacture products with lots of market “Sizzle”

like ToneUP® the world’s first ‘Body Composition Change Product’, already proven in the

Australian market place to be capable of generating Gross profits in excess of $10million if

marketed nationally and clinically proven in university trials to reduce fat and increase muscle

mass without change in diet or exercise.

Competitive Advantages• API’s (Active Pharmaceutical Ingredients)

• Unique diagnosis reversing medicines.

• Strong Pipeline of products

• Paradigm shifting treatment options

• Multiple distribution channels established

• Real market experience, back robust projections

• Strong management team with proven record

Key Investment Highlights• Rapid growth with good market uptake achieve already

• High margin products in a high growth sector

• Revenues achieved in the first year

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search forJubilent Health.

Board & Management:

Norman Ohl - Director/ Company SecretaryNorman is the founder of Jubilent Health Aust. Limited and brings a wealth of management and entrepreneurial acumen to the Company. Long track record of high growth high value business

Peter Degnian - DirectorB.PharmPeter has been a registered pharmacist since 1983 and still active in retail and patient interaction

Cathrine Dahlgren - DirectorM.AppSc (App Chem), Dip. Bus (F’line M’ment)This vast experience, including work with Sigma Nutraceuticals/Herron Nutraceuticals, Progen , Mediherb, provides solid regulatory expertise to the Compan.

Mario Gattino - DirectorApp Sc( Med Admin), MBA ( Exec), Dip Bus (M’ment)Mario Gattino is a former global VP level senior executive with Pfizer Inc., the world’s leading biopharmaceutical company, with extensive international experience.

Corporate StructureAustralian Public Company

Exit StrategyJubilent Health hopes to list on a suitable exchange at an appropriate time.

9

MEDICAL DEVICE

Board & Management:

Dr David Fisher - Director 1st Class Honours Rural Science; PhD Chemical Engineering; Masters in Applied Finance and InvestmentsDavid is a founding Venture Partner with Brandon Capital Partners. David was CEO of Peptech Limited. Prior to Peptech, David spent ten years with Pharmacia AB (now part of Pfizer, Inc). David is a past president of the Australian Biotechnology Association and past chairman of the CSIRO’s Division of Animal Production Industry Advisory Committee.

Andrew Maxwell - Managing DirectorMBA, MAcc, ACPA, MAICDAndrew has a proven track record of entrepreneurial business success in Australia and Asia spanning over 25 years. Andrew is the former CEO of ESCOR Private Equity (a Smorgon Family Company). Prior to joining ESCOR, Andrew was a serial start-up company entrepreneur with a history of successful company launch, business growth and exit.

Corporate StructureProprietary Limited Company.

Exit StrategyThe exit plan for investors is via a listing on an appropriate exchange or a trade sale.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Global Kinetics.

Executive SummaryGlobal Kinetics Corporation (GKC) provides point of care measurement and reporting of

Parkinson’s disease (PD) motor symptoms for neurologists and professional carers to manage:

• Surgical and pharmacological interventions to treat dyskinesia;

• Routine pharmacological treatment of bradykinesia and dyskinesia; and

• A means for patients to manage their therapeutic compliance.

Adoption of the PKG System will result in better patient clinical outcomes, lower patient

management costs and a better quality of life for PD patients. The addressable market in

Europe, US and Australia is $345M+ which represents only 20% of the 12M+ people forecast to

have PD by 2015. The company forecasts annual revenue of $20M+ and NPAT of $8M within the

five years.

Competitive AdvantagesGKC’s core intellectual property is founded on sophisticated software that differentiates

clinically important movement from normal movement and reports this as a bradykinesia and

dyskinesia score.

This intellectual property is protected by:

• Patent;

• Unique domain expertise of the GKC team;

• Retaining data management services in-house limiting access to GKC’s proprietary

algorithms and data library; and

• Investing in ongoing research and development alone and in partnership with the Howard

Florey Institute.

Key Investment Highlights• Solving a significant unmet need in the management of PD;

• A large and growing global market;

• Unique and defendable intellectual property;

• Regulatory approval in Australia, United Kingdom and Europe;

• Engagement with key industry stakeholders;

• A team that has a proven record of delivering value for shareholders.

Global Kinetics Corporation

Medical Devices

2007

Commercialisation

Melbourne

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

10

BIO TECH

BioDiem Ltd (ASX:BDM)

Biotechnology

2004 (IPO)

Commercialisation

Melbourne

Company Name

Sector

Year Established

Business Stage

Location

Executive SummaryBioDiem is a vaccine company developing vaccines for both treatment and prevention of

disease. The leading technology is the LAIV (Live Attenuated Influenza Virus) which was

launched in India in July 2010 as an intranasal vaccine for prevention of swine ‘flu. The LAIV is

also in development for seasonal and other pandemic influenzas. Sales from these products

would generate royalties for BioDiem. The first royalties flowed in 2010. BioDiem is also

developing the LAIV for use in non-influenza vaccine design to produce vaccines for cancer

and infectious diseases. BioDiem intends to generate income from sale of licences to other

vaccine manufacturers for use of the LAIV vaccine design system.

Current Projects• Successful commercialisation of the LAIV technology (launch of Nasovac™ in July 2010)

• In-house vaccine development skills to expand LAIV uses

• GMP materials available for LAIV development (virus and cell bank)

• LAIV induces a broad immune response - mucosal, systemic and cell-mediated responses

• High yield manufacture in egg & cell-based production - to meet pandemic need

• Extensive clinical trial and on-market experience (100m doses) in Russia (egg-based)

vaccine has established efficacy and safety

• Intranasal delivery eliminates need for needles and trained personnel

• Cell-based production provides advantages in bird (avian) flu outbreak when egg supply for

standard flu vaccine production could be compromised.

Key Milestones & Investment Highlights• Global market size in 2009: US$22.7b (US$36.5b in 2013)

• High growth market: CAGR 2008-2013: 13%

• There remains a high level of unmet medical need - >40 human disease pathogens without

effective vaccines

• High barriers to entry with little generic competition

• LAIV pandemic influenza applications already marketed and generating revenue

• First launch of LAIV based vaccine (Nasovac) for pandemic H1N1 (swine flu) in Indian market

in 2010. Royalty payments from sales into private sector commenced.

• LAIV vector project commenced to maximize value of asset.

• LAIV vector applications aim produce early revenue via research and commercialisation

licences.

Share Information

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:BDM

8,524,208

$0.00840

0.200

0.0790

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for BioDiem .

As at 9 December 2011

ASX:BDM 6 month price chart

0.12

0.10

0.08

0.250.200.150.100

Volume (mil/1d)

Jul 2011 Aug 2011 Sep 2011 Oct 2011 Nov 2011 Dec 2011

Board & Management:

Hugh Morgan AC - ChairmanLLB, BComHugh Morgan is Principal of First Charnock. He is a member of the Lafarge International Advisory Board; an Emeritus Trustee of The Asia society New York; Chairman Emeritus of the Asia Society AustralAsia Centre; and President of the National Gallery of Victoria Foundation.

Julie Phillips – Executive Director & Chief Executive OfficerBPharm, MSc, MBAMs Phillips was appointed to the position of Chief Executive Office on July 1, 2009 and was appointed a director on May 7, 2010. She has worked as the CEO and director of start-up Australian biotechnology companies in the life sciences sector.

Larisa Rudenko - DirectorMD, PhD, DScProfessor Rudenko is Head of the Virology Department in the Institute of Experimental Medicine, St. Petersburg, Russia. She is recognised as one of the world’s leading experts in live attenuated influenza vaccines.

11

BIO TECH

Xenexus Pharmaceuticals Pty Ltd

Biotech/Pharmaceuticals

2008

Early stage

Sydney

Development Capital

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Executive SummaryXenexus is undertaking R & D on existing drugs in new indications to secure new use patents

on these re-profiled drugs. The company focus is on:

• Japanese pharmacopeia – drugs only ever registered in Japan

• Drugs with good safety profiles

• Unmet medical needs in large markets

• Low complexity trial requirements

• In-vivo studies and Phase IIa trials where relevant

• Pharma partnerships and out-licensing at early Phase II trial stage

• VC and grant financing where appropriate for each project

Competitive AdvantagesXenexus Pharmaceuticals is pursuing a low risk, low cost business model:

• Xenexus has access to some of the best labs in the world to do low costs animal studies

• Leading scientists in their field who have developed “gold standard” drugs are on the

Xenexus Scientific Advisory Board and are shareholders in the company

• Xenexus drugs have know safety profiles, which dramatically increases the likelihood of

Xenexus re-profiled drugs reaching the market

• Low cost and complexity Phase IIa trial requirements

• Small experienced team, having previously built Nuon Therapeutics Inc

Key Investment Highlights• A proven management team

• An outstanding Scientific Advisory Board

• A low risk, low cost Business Model

• A successful track record with Nuon Therapeutics

• Positive in-vivo data in XEN-101 gout, with patent lodged

• Chronic gout is an unmet medical need

• Positive in-vivo data XEN-102 multiple sclerosis with patent being lodged

• MS an unmet medical need

• XEN-102 is anti-inflammatory and likely neuroprotective

• Two additional programs currently at in-vivo screening stage

Board & Management:

Dr Michael L Selley - Chief Executive OfficerPh.DPreviously the Founder and Chief Scientific Officer for Nuon Therapeutics. Academic at the John Curtin School at ANU.

Prof Sir Marc Feldmann - Director and Member of the Scientific Advisory BoardM.B., B.S., Ph.D., FRCPath, FRCP, FMedSci, FAA, FRSProf Steinman is head of the Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College London.

Professor Larry Steinman - Member of the Scientific Advisory BoardB.A., M.DProfessor, Departments of Neurology and Neurological Sciences, Stanford University

Jay Hennock - Chief Operating OfficerB.EcWorked in corporate advisory with Citibank and Bank of America. A founding shareholder and CFO of Nuon Therapeutics.

Corporate StructureXenexus Pharmaceuticals is a NSW Registered private company.

Exit StrategyXenexus aims to list on a suitable exchange at an appropriate time, or pursue a trade sale.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search forXenexus Pharmaceuticals.

12

Executive SummaryOur objective is to grow a consumer health company by developing or acquiring high potential

brands or products and selling them through retail and online channels. Our brands can be

summarised as follows:

Herb Valley : Well established range of supplements and personal care products sold

exclusively through the health food channel.

Activecare : Developing range of pharmacy only complementary medicines

Activelife : An open brand of personal care products including a Paw Paw Lip Balm and

Aluminium Free Deodorants and Anti-Perspirant.

Sports-haler : Innovative medical device for the delivery of Ventolin and Asimol.

Stay-Healthy : A wholly owned subsidiary established to develop direct to consumer online

and catalogue sales.

Competitive Advantages• Core of innovative and unique products

• Low cost base

• National sales team

• Established customer base and distribution network

Key Investment Highlights• Sales growth 444.76%

• Customer growth 151.96%

• Acquisition of Herb Valley

• Acquisition of Sports-haler

• Launch of Activelife personal care range

• Launch of Chia Seed Oil & Natralgesic Complementary Medicines

• Development of brand and Stay Healthy Club web sites

• Re-packaging and positioning of Herb Valley

Board & Management:

Joe Bayer - ChairmanBBus (Acctg) CPA MAICDFormer Executive General Manager, Mayne (Faulding) Pharma Asia Pacific and Mayne Consumer Products.

Geoff Crittenden - Managing DirectorBSc(Hons)Eng CengAn experienced entrepreneur who has held senior executive appointments in Australia and overseas.

Rakesh Raj - DirectorMBA BSc EngSenior pharma executive former Director Pharmacy Division, Sanofi-aventis and GM Sales Sandoz.

Craig Stokoe - DirectorMD of LPN, a leading marketing and design consultancy.

Exit StrategyTo grow sales to more than $10 million within the next five years and look for trade sale or buy-out opportunities.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Cynergy Health.

HEALTHCARE

Cynergy Health

Consumer Healthcare

2008

Development

Sydney

Company Name

Sector

Year Established

Business Stage

Location

13

Executive SummaryElemental Energy Technologies has been formed to commercialise its breakthrough third

generation marine turbine technology employing a robust and proven business model. In

conjunction with international manufacturers, distributors and partners the company is

building a sound platform for profitable growth as new global marine energy markets develop

and grow.

Elemental is in the process of optimizing the construction and trialling of its proprietary Sea

Urchin turbine system in 1, 2, and 10 megawatt configurations. Ocean currents, tides and

flowing rivers are an increasingly recognised major green energy source that will attract

billions of dollars of new infrastructure investment in the years to come. UK-based energy

industry consulting firm, Douglas Westwood, has projected that the size of the marine energy

market alone will be in the order of US$1 trillion.

Competitive AdvantagesThe SeaUrchin represents a major advancement over the first generation marine generator

technologies commonly in use today, offering:

• An efficient design that generates up to 4 times the power of competing systems

• 70% more efficient than “propeller”style marine generators

• Scalable – sub 2kW units, ideal for small scale markets.

• unit arrays are planned for very large scale ocean based developments

• Reliabity. Only one moving part with no gear box required.

• Efficient at low and high flow rates making it suitable for the widest range of locations

including ocean streams, ocean tides and flowing rivers around the world

• Self aligning design optimally aligns for continuous flows and changing tides

Key Investment HighlightsElemental’s technology is more efficient and powerful than competitors, and can be built at

lower cost. It is a highly scalable generation solution, from the micro level to large turbine

arrays. The Sea Urchin provides predictable base load power.

Elemental already has in place licenses with key partners in several potentially lucrative

market. The company has funds already committed for its expansion and has a defined exit

strategy, targeting either an IPO on a suitable exchange or a trade sale.

Board & Management:

Kim Lyle – Executive Director and ChairmanFormerly head financial analyst for Amoco Australia and sales manager (fixed interest) for stockbroker ANZ McCaughan. Has served on the boards of two ASX listed companies and has 12 years experience in facilitating capital raisings.

Michael Urch – Executive Director (Research and Development) Graduated from Sydney University in 1995 with 1st class honours in Mechatronics, which combines mechanical, electrical, electronics, robotics and com-puter engineering with management practice. Since graduating Michael has worked at an executive level in project management.

Larry Luo – Non-Executive DirectorLarry holds a Bachelor Degree in Mechanical Engi-neering from the University of Shanghai for Science and Technology and came to Australia in 1990 after working in Shanghai Shangling Group as a technical design engineer for three years.

Corporate StructurePublic Unlisted Company

Further InformationTo learn more about this opportunity, go to www.wholesaleinvestor.com.au and search for Elemental Energy Technologies.

Elemental Energy Techologies Ltd.

Cleantech/Renewable Energy

Commercialisation

Sydney, NSW

$4 million

Company Name

Sector

Business Stage

Location

Seeking

RENEWABLE ENERGY

14

Current ProjectsProject 1: Little Takas nappies and Bamboo baby wipes – Australia

EcoQuest launched the Little Takas nappies and Bamboo baby wipes range

in Australia in October 2010. The products are now stocked in over 300 retail

stores across Australia, including Toys R Us, Baby Kingdom, Franklins, and a

growing number of IGA stores, promoted and sold through 4 leading nappy

e-tailers and on its own e-commerce website www.littletakas.com.

Project 2: Little Takas nappies and Bamboo baby wipes – UK and US

EcoQuest has launched the Little Takas nappies and Bamboo baby wipes range

in the UK, focusing initially on internet sales such as resell through the website

of the UK’s largest parenting charity for parents the National Childbirth Trust

(NCT) www.nct.org.uk. The company will approach US brokers in Q4 of 2011.

Project 3: Little Takas nappies and Bamboo baby wipes - Asia

From July 2011, Ecoquest entered the Asian market. The Little Takas range is

sold in three different Hong Kong supermarket chains including Three Sixty

(Hong Kong’s largest organic and natural food store), Marketplace (a high

end supermarket chain) and Wellcome (Hong Kong’s longest established

supermarket chain). The company plans to expand into other Asian countries.

Competitive Advantages• EcoQuest addresses a major growth market - as major contributors to landfill,

disposable nappies represent one of the world’s biggest environmental

problems, taking over 100 years to break down. The Little Takas nappies and

Bamboo baby wipes ease consumer consciences but fit into modern

lifestyles.

• EcoQuest has a highly experienced team, including global eco-nappy and

consumer sales experts

• EcoQuest has technology that is proven by both rigorous consumer testing

and meets stringent industry standards

• Ecoquest is already engaged in developing a second generation nappy which

will increase its use of sustainable materials whilst retaining its

biodegradeable credentials

• EcoQuest is listed on the ASX, and therefore provides both the potential for

excellent capital gain, and the flexibility of sale of shares through the ASX

Executive SummaryEcoQuest Limited, the clean technology company developing biodegradable

disposable personal care products from sustainable sources, has started

to realise its global market strategy with the Little Takas 90% biodegradable

nappies and 100% biodegradable bamboo wipes range on sale in a growing

number of retail and e-tail stores in the UK, Asia and Australia as well as through

its own website www.littletakas.com.

The company is in talks with major Australian retail chains and is conducting a

strong marketing and PR campaign across print, broadcast, online and social

media to increase awareness and drive sales.

The company wants up to 5% market share of the total Australian nappy market

and plans to grow the eco market and become the eco-nappy of choice for

Australians based on its superior sustainable content, higher total product

biodegradability, better performance, better margin to retailers and lower retail

price (in its segment).

The Australian eco nappy market is expected to grow by more than 25% per

annum. The company’s mission is to create a globally recognised brand of

biodegradable personal care products based on proven and tested principles of

sustainability.

The company will also continue developing and protecting its intellectual

property, while refining and growing its product range.

EcoQuest Ltd

(ASX:ECQ)

Cleantech

2007

Trading

Western Australia

Company Name

Sector

Year Established

Business Stage

Location

CLEAN TECH

Share Information

ASX:ECQ 6 month price chart

0.03

0.02

0.01

0.00

54321

Volume (mil/1d)

Jul 2011 Aug 2011 Sep 2011 Oct 2011 Nov 2011 Dec 2011

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:ECQ

1,086,043

$0.0070

0.0830

0.0060

As at 9 December 2011

15

Key Milestones & Investment Highlights• September 2010 - 1st order (1m units) Little Takas nappies distributed to

independent supermarkets

• October 2010 – Official product launch of Little Takas nappies and Bamboo

Baby wipes

• December 2010 – product stocked in 249 stores across Australia

• January 2011 – 2nd order (2m units) arrives in Australia

• January 2011 – new Little Takas website with global e-commerce functionality live

• February 2011 – first revenue deposited

• May 2011 – UK market launch

• July 2011 – New Managing Director appointed

• July 2011 – Asian market launch

• August 2011 – in discussions with major Australian retail chain

• September 2011 – Major wholesale chain Metcash agrees to carry the full

EcoQuest range

• September 2011 – The National Childbirth Trust in the UK has agreed to stock

and sell the Little Takas products on its website.

Latest News & Announcements• 18.5.11 EcoQuest enters UK market with Little Takas

• 23.5.11 Australian e-tailer to sell Little Takas

• 27.6.11 Little Takas to be showcased in maternity packs

• 20.7.11 EcoQuest appoints global chief executive

• 29.7.11 EcoQuest launches Asian market entry in Hong Kong

• 29.8.11 Metcash & The National Childbirth Trust to offer Little Takas

Board & Management:

Sylvia Tulloch - ChairmanMscRespected scientist and entrepreneur with over 25 years experience in the establishment and management of high tech businesses.

Keith Herbert - Global Managing DirectorHighly respected FMCG executive previously in charge of PZ Cussons commercial operations across Europe, the Americas, Asia and Australasia.

Matthew Hicox - General Manager & Sales Marketing Manager, AustralasiaOver 18 years in sales and marketing, particularly in the FMCG & Pharmaceutical sectors.

Michael Greenup - Director of Operations & Procurement 35 years experience of owning and operating successful businesses, including 12 years consulting and sourcing in China and Malaysia.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for EcoQuest (ASX: ECQ).

CLEAN TECH

16

Executive SummaryBioPower Systems is focused on developing advanced technologies which convert the energy

in waves and tides to grid-ready electricity. Developed by a group of professional engineers

with a deep understanding of the challenges posed by harnessing ocean energy, the designs

address all the problems that have been experienced by other technologies. In achieving this,

ocean engineering principles have been augmented with survival and performance concepts

drawn from natural marine species such as kelp and sharks. This use of “biomimicry” leads to

wave and tidal system designs that are simpler, easier to install, and less expensive on a $/

MWh basis, than other ocean energy technologies.

Competitive AdvantagesBioPower’s primary technology, a wave energy system called bioWAVE™, is designed to sway

back and forth beneath powerful swell waves while capturing the energy and converting it into

electricity.

The key advantages of the bioWAVE technology are:

• High efficiency of energy capture, with in situ (onboard) conversion to high voltage

electricity, and direct low-loss transmission power to grid

• Ability to streamline by lying flat against the seabed during extreme conditions, enabling

extreme weather survival at low cost

• Simple low-cost installation, requiring only standard service vessels

• Detachable power conversion module, allowing for simple low-cost maintenance procedure

• Zero visual impact and minimal affect on the environment.

Key Investment Highlights• BioPower employs 6-10 specialised professionals

• Extensive network of partners/alliances

• Occupy office plus adjoining Test Centre in Sydney

• 100 percent owner of IP, including over 28 individual patents (granted and pending)

• Demonstration project in late stages of development:

250kW grid-connected bioWAVE™

$14 million budget

4 year duration in total

Validation after 6 months

13 project partners

Planning, design, development near complete

Installation scheduled for 2012/13 summer

Board & Management:

David Iverach – Chairman BE, PhDDr Iverach has over 40 years experience at the executive level in the public and private sectors.

Timothy Finnigan – Managing DirectorBASc, MASc, PhDDr Finnigan has been involved in ocean engineering for 18 years.

Bill Highland – Non-executive DirectorB EngMr Highland is an investment manager with CVC Investment Managers Limited and has extensive general management experience.

Aaron Spicer – Non-executive DirectorB. Com, MBAMr Spicer is a Director of Lend Lease’s venture capital business..

Corporate StructurePrivate company limited by shares. Significant shareholders include Lend Lease Ventures, CVC REEF,

and CVC Sustainable Investments.

Exit StrategyTo find a global technology company to become a cornerstone investor.

Further InformationTimothy Finnigan 0488 587475 tfinnigan@biopowersystems.com

BioPower Systems Pty Ltd

Renewable Energy

2006

Commercialisation

Sydney

$6 million

Company Name

Sector

Year Established

Business Stage

Location

Seeking

RENEWABLE ENERGY

17

FMCG

Eastern Harmony New Zealand Limited

FMCG

2011

Commercial – Phase 1

Australia, New Zealand, Hong Kong, China

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Executive Summary• EHNZ is a wholesaler/distributor of NZ milk powder products in the North Asia region

• Premium NZ milk powder products are in high demand in mainland China (in particular) and

other developed Asian nations

• EHNZ has signed a long term distribution agreement for Mi-NZ, a new NZ made premium

infant milk formula

• Strategic distribution alliance being finalised (letter of intent received) with a highly reputable

Chinese government owned trading company (SOE)

• Expressions of interest have been received from other mainland Chinese customers

• Lease terms agreed for a retail property and sales office located in a duty-free trading zone

on the border between HK and China to support own sales of Mi-NZ

Competitive Advantages• Low cost importer and distributor in key Asian markets

• Exclusive distribution rights for Mi-NZ IMF product range in Hong Kong, Macau, and 19

Chinese provinces; plus first right of refusal over Japan, South Korea, Taiwan and Singapore

• Strategic distribution alliance with a Chinese SOE

• IMF entry barrier overcome due to access to dairy product import license through Chinese SOE

• Retail shop and sales office in a duty-free trading zone on the border between Hong Kong

and China to support own sales of Mi-NZ

• Other strategic alliances with distribution and retail partners in mainland China

• Import duty removal from 2012 under FTA between NZ and China

Key Investment Highlights• Infant milk formula (IMF) is projected to be the fastest growing food and beverage segment in

China over the next five years

• NZ sourced premium IMF is viewed by customers as a proxy for quality

• EHNZ has secured exclusive distribution rights for Mi-NZ IMF product range in key markets

• Strategic alliance being finalised with a Chinese SOE to facilitate China Import and Quarantine

licensing, importation and sub-distribution in Southern China

• Negotiating further alliances in respect of other wholesale/retail distribution channels in

China to ensure that customers receive genuine quality premium NZ milk powder products

• Retail shop and sales office presence in Shenzhen, China, duty-free zone

• Immediate market opportunities in Hong Kong and China due to recent local IMF scandals

and contamination concerns over Japanese imported products

• Access to additional premium IMF brands to support alternative distribution channels

Board & Management:

Edward Stauber - CEOPreviously Vice President of Asia Pacific, Novartis Vaccines & Diagnostics

Randolph van der Burgh - CFOPreviously Partner, Ernst & Young

Michael Lees - COOPreviously Director Structured Asset Finance, HSBC Hong Kong

Linda Cheung - COO, HK & PRCSelf-employed marketing consultant for the past 15 years

Corporate StructureEHNZ is a New Zealand registered private company (CN 1550480)

Exit Strategy• The short to medium-term strategy is to grow the business naturally and/or by acquisition• Should the right opportunity arise, EHNZ would consider a sale to a strategic investor or IPO

Further InformationTo learn more about this opportunity, go to www.wholesaleinvestor.com.au and search for Eastern Harmony.

18

Web Solutions Your Online Success

TECHNOLOGY/INTERNET

Executive SummaryExa is Australia’s largest Online / Apps / Web / Mobile company, with over 1000 clients.

Exa generates significant recurring revenue from its client base and is ranked at the top of

Google for online marketing, tools and technologies.

Exa operates 24x7, 365 days per year, is the most efficient player in its space and has unique

ecommerce solutions for a range of social media and smart phone technologies.

The business maintains high margins due to over $10M+ invested in back end & support

systems.

Exa is well positioned to capitalise on the rapid growth in the digital economy and is seeking to

raise up to $2M for product and geographic expansion.

Competitive Advantages• Senior Management are equity holders

• Leading edge technology (Online / Apps / Mobile)

• Cost Efficient

• National Footprint

• Brand

• Broad client base

• Explosive growth in mobile apps

• Genuine 24x7x365 operations

Key Investment Highlights• Experience Board & Management Team

• International Market Potential

• Blue Chip Client Base (top tier banks)

• Multiple revenue streams

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for Exa Web Solutions.

Exa Web Solutions

Internet, Technology

2000

Expanding

Melbourne, Australia

$2 million

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

Peter Ball - Managing Director M.D.25 years of building successful technology companies.

Mitch How - CFOLawyer and CPA4 years at EXA. Similar previous roles in Media, Music & Tourism in Australia, UK & Europe.

Jim Vincent - Special Operations Manager B.Sc, Maths, Physics & Comp 30 Years @ IBM. Programs in 22 languages, 6 patents and extensive patent work.

Corporate StructurePrivate Company Limited by shares.

Exit Strategy: Exa aims to list on a suitable exchange at an appropriate time.

19

TELCO/FINANCIAL SERVICE

Mint Wireless Limited (ASX:MNW)

Telco/Financial Services

Early

Sydney, Singapore, Kuala Lumpur,

London

Company Name

Sector

Business Stage

Location

Executive SummaryMint Wireless Limited (Mint) is a global payments and mobile transactions company listed on

the Australian Securities Exchange (ASX: MNW). Mint’s core business specifically focuses on

the developed and emerging markets.

Our vision is “To become the largest, global micro-transactions processing company for the

poorly banked and cash economy”

Mint’s subsidiary, Intermoni is unique from other mobile money solutions that are evolving

globally:

• ‘Bricks and mortar’ deployment and front end, bridging market gaps between the developed

online world and the poorly banked, cash economy

• Scalable: self-service ‘plug-and-play’ cash acceptance kiosks – simple to operate with ability

for rapid deployment

• Focus on micro valued transactions below USD$20

Current Projects• Malaysia – First developing country deployment and roll out of micro-transaction terminals.

Malaysia is the 2nd largest remittance-sender country amongst developing countries with

~2.4 million migrants remitting $6.8 billion annually. Binding order received from distributors

in July 2011 for 3,000 terminals in Malaysia over the next 6 months (valued at ~ USD$5M).

• Opening new markets in Asia (discussions underway in Indonesia, Singapore, Hong Kong and

Vietnam markets) with further opportunity to scale globally.

• Advanced discussions with leading microfinance cooperatives in one of the most vibrant

microfinance countries in the world for the use of Intermoni’s micro-transaction terminals for

the repayment of micro-loans.

Key Milestones & Investment Highlights• Successful launch of Intermoni (fully owned subsidiary of MNW) in Singapore, focused on

deploying micro-transaction services to the poorly banked population of emerging markets

globally

• Acquisition of 51% of J&C Pacific in Malaysia, immediately providing the Company with

operations and revenues in Malaysia and mobile technology and infrastructure that the

Company will use as a base to develop its suite of micro-transactions services

• Excellent progress with terminal rollout: Orders received for 3,000 terminal in Malaysia over

the next 6 months and advanced discussions with key partners in other South East Asian

markets

• Capital raising: Balance sheet strengthened with over $2 million raised via institutional

placement and share purchase plan

Board & Management:

Terry Cuthbertson - Non-Executive Chairman B.Business, ACAChairman of seven ASX listed companies. Wide corporate finance experience (including merger and public offerings) as well as with the IT industry.

Alex Teoh - CEO & Managing DirectorB. Science (Information Systems / Finance)Extensive experience in Australasia with global management consulting practices specialising in the IT & Telco sector.

Dr. Seng Chuan Tan - Non-Executive Director Mechanical engineering, Masters and Ph.D in Engineering and ScienceExecutive Director of Malaysian KLSE listed Insas Berhad. Wide experience in the IT and payments industry.

Andrew Teoh - Executive DirectorBachelor of Commerce (Accounting/ Finance)Extensive experience with emerging consumer and telecommunication technologies with prior experience in the pre-paid Telco industry.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Wireless Limited (ASX: MNW).

Share Information

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:MNW

11,208,351

$0.0450

0.1500

0.0200

As at 9 December 2011

ASX:MNW 6 month price chart

0.10

0.08

0.06

0.04

3210

Volume (mil/1d)

Jul 2011 Aug 2011 Sep 2011 Oct 2011 Nov 2011 Dec 2011

20

TECHNOLOGY/FINANCIAL SERVICES

Executive SummaryEquiome is a specialist financier of all aspects of large corporate software projects, which

allows companies to realise immediate commercial benefits from the usage of the solution,

without the risk of project failure or the requirement for any capital investments. This, aligned

with Equiome’s rapid deployment methodology and partnering approach, creates a totally

unique customer value proposition that addresses the three biggest challenges facing

customers commencing large software projects; initial funding, alignment of costs to benefits

as well as project execution capabilities. This solution has major benefits for a wide range of

large corporations, both in Australia and Internationally.

Competitive Advantages• Equiome’s model is a totally unique and new way of resolving a business problem common to

large software project in most major corporations

• The solution is designed to easily scale, providing multiple streams of business benefits for

each customer

• Equiome is technology and vendor independent, giving customers more control

• Equiome funds all aspects of the software project

• Equiome charges a single monthly fee for all aspects of the solution

• It is one of the few approaches that look at the problem from a business benefit/output,

rather than a series on inputs

• Have developed a rapid deployment methodology, with a heavy focus on the realisation of

quantifiable business benefits

Key Investment Highlights• Highly experienced leadership team who clearly understand the market and the intrinsic

value of software projects

• Equiome is creating a new investment asset class, by transforming the current intangible

software assets, into tradeable commodities

• The model is based around initial and annuity revenue streams

• Equiome is in active discussions with a number of major Australian organisations for this

solution

• The model is based around the re-usability of solutions; small, incremental changes can

create significant value

• Equiome has invested significant time to create and develop relationships with major

companies to deliver this solution

• This model is absolutely unique, and has a substantial domestic and International market

Board & Management:

Steve Hanna - Managing Director A background of 25 years in IT, working for large technology vendors, holding key roles in software sales and vendor finance

Corporate StructureEquiome Pty Ltd is a privately held Australian company.

Exit Strategy: Equiome is aiming for revenue and asset growth, followed by a strategic trade sale in 3 – 5 years.

Equiome

Technology / Ecommerce / Finance

2007

Early Commercialisation Stage

New South Wales

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for Equiome.

21

SUPERANNUATION

Executive SummaryInvestment Administration (InvestAdmin) provides a complete, robust, scalable, technology

based solution for the end-to-end administration of Self Managed Superannuation Funds

(SMSFs). This solution is available on a wholesale basis to SMSF fund administrators including

accountants, stockbrokers, financial planners and wealth managers.

InvestAdmin offers SMSF Administrators a ‘back-office’ service. Branded as SMSF+, the

application gathers financial data in real time from the ASX, stockbrokers, banks, & fund

managers. This stored data is managed to provide relevant tax, audit & portfolio information for

end-users and financial intermediaries.

The company is ready to exploit opportunities in the SMSF sector and seeks $2.5m to scale up

to full commercial operations and implement its aggressive marketing, merger and acquisition

program.

Competitive Advantages• Commercialisation of SMSF+; a platform based SMSF administration application

• Gaining an AFSL – anticipated in December 2011.

• Launch of a unique term-life insurance offer to SMSF clients in January 2012

• Development of a full Administration Centre

• Expansion of administration application to include non super assets

• Inclusion of an intermediary and trustee compliance training multimedia interface

Key Investment Highlights• Original platform developed for major listed financial services group. Same development team

now running Investment Administration/SMSF+ development

• Raised additional $1.25m seed capital in 2009/10 for customisation and operational trial

• Successfully completed live trial of SMSF+ from December 2010 to October 2011

• Established experienced executive and management teams

• Established operational office /base in Adelaide

Board & Management:

Peter Bartleet - ChairmanExperienced executive at both private and public company level. Has had several years experience in the Venture Capital industry

Ludwid Bachmayer – Chief Operational OfficerFormerly General Manager of Client Services for State-wide Superannuation and IOOF Trustees, with a team of 75 people. Holds a Diploma of Financial Services.

Paul Massey – Marketing DirectorFormerly State Manager of Compliance and Retail/Financial Services for CBA and NAB. Holds DFP 1-3 and PS-146 qualifications.

Damian Taylor – Technical DirectorThe Architect of InvestAdmin’s SMSF administration platform and application. Formerly CEO of AET Super Solutions and is a qualified SMSF specialist with a PS-146 qualification.

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for Investment Administration.

Investment Administration Pty Ltd

Superannuation

2007

Commercialisation

Adelaide and Melbourne

$2.5 million

Company Name

Sector

Year Established

Business Stage

Location

Seeking

22

PROPERTY

Executive SummaryBlackWall SPORTSMED Property Trust is a fixed term property investment trust that has

contracted to acquire the SPORTSMED Hospital and adjacent SPORTSMED Clinic in South

Australia, a leading orthopaedic and sports injury practice with over 130,000 patients per year.

The Trust is forecast to generate tax effective distributions starting at 9% per annum paid

quarterly. Investments are not diluted by acquisition costs and an initial investment of $1.00

per Unit will be backed by 100 cents of NTA. Rental income is forecast to grow by at least 3% per

annum. BlackWall is a real estate investment linked to the fast growing and non-discretionary

healthcare industry.

Competitive Advantages• Strong lease covenant to a highly regarded operator on a triple net lease with 20 year term.

SPORTSMED was rated as the No.1 private hospital in a recent Medibank survey.

• Alignment of interest. SPORTSMED has first rights of refusal to purchase the asset as a co-

owner and will retain 25% ownership.

• BlackWall is a vertically integrated property funds management business. Its directors and

senior managers have structured and managed direct property investment since the early

1990’s. Trusts structured by Blackwall of a similar type have paid all distributions through the

GFC and shown strong capital growth.

• As a special offer to Wholesale Investor subscribers BlackWall will rebate brokerage of 2% to

each investor investing through the special Wholesale Investor webpage. With this offer the

total cash return in the first year will increase to 11%.

Key Investment Highlights• Strong cash yield of 9% pa paid quarterly with tax benefits.

• The Trust is structured to minimise transaction costs and, as such, investors’ initial NTA is

100 cent per $1 invested thus enhancing capital returns.

• The trust has been given a AA- rating by Property Investment Research (PIR) which indicates

that PIR believes it is an above-average grade product, exceeds the minimum requirements

of its review in a number of key evaluation parameters and has an above-average risk/return

trade-off.

• The Trust should be able to consistently generate above-average risk adjusted returns.

BlackWall SPORTSMED Property Trust

Property Investment

2011

Adelaide , South Australia

$10.6 million

Company Name

Sector

Year Established

Location

Seeking

Board & Management:

Stuart Brown - Chief Executive Officer and DirectorMore than 15 years experience in property investment. Involved in debt and equity raisings on listed and unlisted property valued at more $500 million. Formerly with leading law firms Mallesons and Gilbert & Tobin.

Richard Hill - Independent Chairman and Non-Executive DirectorExtensive investment banking experience in the US and Hong Kong. Founding partner of corporate advisory firm Hill Young & Associates. Chairman of the Westmead Millenium Institute for Medical Research.

Joseph (Seph) Glew - Non-Executive Director Over 20 years experience in the commercial property industry in NZ, Australia and the US. Non Executive director with a number of listed companies in NZ and Australia.

Robin Tedder - Non-Executive Director Over 30 years experience in investment and financial markets. Chairman of Vintage Capital and a former member of the ASX.

Corporate StructureSingle asset special purpose trust registered as a Managed Investment Scheme under the Corporations Act 2001.

Exit StrategyAsset sale on expiry of the 7 year term.

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for BlackWall.

23

FUND MANAGEMENT

Bizpanel Limited

Finance and Investment

2011

Operational and seeking investors

Sydney

$5m initial

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Executive SummaryThe Company operates in the franchise industry and offers three (3) key services:

• Licensees –– Bizpanel owned Franchises with a Licensee acting as the “Franchise Manager’

under agreed terms; and

• Franchisees –– Providing a below 80% Loan to Value ratio, loan for the purchase of an

approved Franchise License. The Franchisee under this arrangement holds the Franchise

License directly and the Company takes a fixed charge over the Franchise as security; and

• Business Support –– Essential services such as bookkeeping and accounting in addition to

desired services such as business planning, business coaching and sales training

The goal of Bizpanel is return based, therefore each of the 3 key services aims to deliver a

minimum return.

Competitive Advantages• Preferential agreements and terms with Franchisors;

• Exclusive funding agreements with franchisor;

• Highly skilled management team professionals;

• High scalability and no direct competition

• Business Support services tracks financial performance to the franchise;

• Bizpanel always retains the right to take-back the Franchise Business, appoint external

management, sell or dispose of the asset.

Key Investment Highlights• Franchise industry specific

• Below 80% loan to value ratio

• Investor places 100% of investment on term deposit for the term of the debenture

• Dual income stream from bank deposit rates and investment

• Foreign exchange options available for offshore investors

• Investors can nominate their preferred franchise

• Franchise sector anticipates double digit growth for 2012

• Investment return expected from 12% pa for funds held on term deposit as security or up to

17,5% pa for direct investment.

• Suitable for superannuation including self managed superannuation

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Bizpanel Limited.

Board & Management:

Matthew Holland - M. Director Financial Planner, RG 146 Diploma financial ServicesThe largest multi franchise owner for a major franchise. Matthew sold in 2011 yielding the largest multi million dollar trade sale for the franchise group.

Chris Kalpage - DirectorSolicitor Chris Kalpage a Solicitor with the Law Society of New South Wales for the past 27 years.

Andrew Garouniatis - DirectorAccountant CorporateAndrew has worked with Blue Chip organisations for the last 26 years. A member of the Institute of Public Accountants.

Anita Olsen - Director Accountant / CPAAnita Olsen started in her accounting practice in 1994 as a registered tax agent and accountant.

Corporate StructureAn unlisted Public company and financial services license number 404453. Daily management is undertaken by Directors Matthew Holland and Chris Kalpage.

Exit StrategyDebentures:Fixed Three (3) or five (5) year term;From 12% - 17.5% per annum;Paid Quarterly, bi annually or annually: May be redeemed early upon application to Bizpanel and the bank.

24

Executive SummaryTRAC Financial Group Ltd (TRAC) is an Australian domiciled specialist portfolio and fund

management firm. Utilising exceptional prior performance, the TRAC Absolute Return Fund

was launched oversubscribed in November 2009. Since inception until 31 May 2011, this fund

returned to investors 102.54%.

TRAC is now pleased to announce the launch of the TRAC Absolute Return Fund – Issue 2,

providing investment exposure to the manager’s successful trading strategies.

Competitive Advantages

Key Investment Highlights• Alternative asset exposure, diversifying against traditional investment strategies.

• Aims to provide investors with consistently high returns irrespective of global market

conditions, with moderate levels of risk.

• Targets a return above the global asset class with the strongest performance.

• Aims to achieve this target by successfully employing discretionary; systematic; arbitrage;

and event driven trading strategies, while continually remaining market neutral.

• Trades across asset classes and over a wide but familiar spectrum of markets around the

globe.

• Will not be limited to the adherence of any specific investment philosophy, but rather

focus on the most effective method of generating profits within the parameters of its risk

management system.

FUND MANAGEMENT

Board & Management:

Thomas Coughlin - Chief Investment Officer 10 + years experience in the Investment and Fund Management industry. Sits on the board of four public investment and commodity public companies.

Michael Coughlin - Company Secretary 37 years experience in the Accountancy and Financial Services industries. 33 years as principal.

William Ralston - Non Executive DirectorProminent Queensland businessman and property developer for 35 + years.

David A Charles – DirectorLLB (commercial); GD Legal PracticeActed for some of the world’s largest and most prominent entities across four continents. An experienced director and a dynamic business oriented lawyer, with a focus on corporate governance.

Corporate StructureTRAC Absolute Return Fund – Issue 2 is a Unit Trust with TRAC ARF 2 Pty Ltd as Trustee. TRAC Financial Group Ltd is the manager.

Exit StrategyMonthly redemptions are available to all investors.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for TRAC Financial.

TRAC Financial Group Ltd

Fund Management

2009

Expansion

Brisbane

Investment Funds

Company Name

Sector

Year Established

Business Stage

Location

Seeking

25

PROPERTY

Executive SummaryFolkestone is a real estate investment, development and funds management company listed

on the ASX (Code: FLK).

Following an Extraordinary General Meeting of Shareholders in March 2011, the New Board and

senior management have recapitalised the Company by successfully raising $31.5m and are

now implementing a new strategy to enable Folkestone to take advantage of the attractive

opportunities created by the dislocation in real estate and financial markets across:

• investment types: direct investment, joint ventures and co-investing in Folkestone managed

funds;

• capital structures – ordinary equity, preferred equity and mezzanine debt; and

• sectors – office, retail, industrial, residential and social infrastructure.

Folkestone’s on balance sheet activities will focus on value-add and opportunistic investments

while Folkestone’s funds management platform (Equity Real Estate Funds Managament) will

offer real estate funds to private clients, high net worth individuals and select institutional

investors across core, value-add and opportunistic real estate investments.

The focus of Folkestone’s investment strategy will be on delivering capital growth for

Shareholders. Folkestone will target an after-tax return on equity of 15% per annum on a rolling

three year basis.

Current Projects• Clifton Hill – Melbourne (residential apartments)

• Altona North – Melbourne (bulky goods/industrial)

• Mickleham – Melbourne (industrial land)

• Karratha - WA (residential accommodation)

• Officer – Melbourne (residential land sub-division)

• Tivoli Development Fund (residential development fund)

Key Investment Highlights• New experienced board and management team

• Alignment of interest – senior management own more than 12% of the Company

• Unique offering in the listed real estate sector

• Positioned to capitalise on attractive real estate opportunities

• Exposure to funds management platform – Equity Real Estate Funds Management

• Strong investment sourcing capabilities

Company Name

Sector

Year Established

Business Stage

Location

Board & Management:

Garry Sladden - Non-executive Chairman Garry is a business and strategic adviser who has a diversified business background in the areas of real estate, private equity, banking and finance.

Greg Paramor - Managing DirectorGreg has been involved in the real estate and funds management industry for more than 40 years. Greg was the CEO of Mirvac between 2004 and 2008.

Ben Dodwell - Head of PropertyBen has been responsible for the development of retail centres, integrated mixed use and apartment projects at Lend Lease and Stockland.

Adrian Harrington - Head of Funds ManagementAdrian is the former CEO of Funds Management, US and UK at Mirvac and has more than 18 year experience in funds management and real estate industries.

Jonathan Sweeney - Chief Operating OfficerJonathan has more than 24 years experience in the finance services industry and was the former Managing Director of the Trust Company from 2000 to 2008.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Folkestone (ASX: FLK).

Folkestone

(ASX:FLK)

Property

1960 – listed on ASX June 2000

ASX Listed

Australia

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:FLK

26,700,201

$0.0720

0.1450

0.0720

Share Information As at 9 December 2011

ASX:FLK 6 month price chart

0.11

0.10

0.09

0.08

0.07

3

2

1

0

Volume (mil/1d)

Jul 2011 Aug 2011 Sep 2011 Oct 2011 Nov 2011 Dec 2011

26

Executive SummaryBullion Capital Limited (BCL) is an Australian domiciled specialist bullion brokerage and fund

management firm. Capitalising on its unique position and strategic advantages within the

physical precious metals industry, BCL is pleased to offer a range of precious metal Bullion and

Ore funds exclusively to Sophisticated and Professional investors.

All funds have investment strategies implemented to provide a relative return over their

underlying spot bullion price, while providing the highest level of quality assurance and safety

in the industry.

Current FundsBCL is offering investment in the following physical precious metal funds:

• Gold Bullion

• Silver Bullion

• Platinum Bullion

• Gold Ore

• Silver Ore

• Platinum Ore

Key Investment HighlightsBullion Funds:

• The investment objective is to marginally outperform the underlying inter-bank bullion spot

price, while providing the safest, most flexible and cost effective allocated bullion

investment vehicle available globally.

• The funds have an exclusive market making agreement with Australian Bullion Exchange

(ABX).

• Real-time trading with 3 day settlement.

• Monthly physical delivery and vault inspection available.

• Currency hedging available.

Ore Funds:

• The investment objective is to significantly outperform the underlying inter-bank bullion spot

price, while providing a safe allocated bullion investment vehicle.

• Sources unrefined metal and sells to refiners at a profit.

• Supply agreement in place with Australian Bullion Refinery.

• Currency hedging available.

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Bullion Capital Limited

Fund Management

2010

Expansion

Brisbane

Investment Funds

Board & Management:

Thomas Coughlin - Chief Investment Officer 10 + years experience in the Investment and Fund Management industry. Sits on the board of four public investment and commodity public companies.

Dylan Kelly - Technical ManagerBBus Com, GCME, M.ScMining financial evaluation specialist. International and cross cultural experience in a variety of commodities and operating environments.

Michael Coughlin - Company Secretary 37 years experience in the Accountancy and Financial Services industries. 33 years as principal.

William Ralston - Non Executive DirectorProminent Queensland businessman and property developer for 35 + years.

David A Charles – DirectorLLB (commercial); GD Legal PracticeActed for some of the world’s largest and most prominent entities across four continents. An experienced director and a dynamic business oriented lawyer, with a focus on corporate governance.

Corporate StructureThe Bullion Capital Funds are Unit Trusts with corporate Trustees. Bullion Capital Limited is the manager of the Funds.

Exit StrategyBullion Funds - Real-Time trade execution with 3 day settlement, plus monthly physical delivery available.Ore Funds - Monthly redemptions.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Bullion Capital Limited.

FUND MANAGEMENT

27

LOGISTICS

Executive SummaryHannan Logistics has branches and fully equipped depots strategically placed in every

mainland capital city of Australia with a head office in Mooloolaba, Queensland, The company

has access to over 300 ISO shipping containers and uses the national rail system for the

shipping of commercial retail furniture and white goods, household furniture and effects and

other specialised goods around Australia.

Hannan has over 80 permanent and casual employees and four main operating divisions:

private removals, government removals, commercial removals and special projects.

The sales by each of the divisions are completed by the depot teams around Australia who

report to the Executive Chairman and National Operations Manager, Col Hannan.

The estimated (annualised) turnover in 2012 will exceed $15.3 million.

Competitive Advantages• Australia wide interstate and territory focus using sealed containers for door-to-door delivery.

• The provision of a high quality value for money customer benchmarked service: The Smartest

Move You’ll Make.

• Strong internal sales and execution efficiencies in a high cost/low margin but reliable

business sector.

• Experienced and well trained employees for the packing, loading, unloading and unpacking of

the customers precious goods and effects.

• Industry growth over the next 10 years is likely to more than double.

• The Hannan Guarantee, which offers to protect the customers against loss and damage risk

• Tailored packages to suit individual families, businesses from timing and schedules to

complete packaging solutions with client branded containers.

Key Investment Highlights• The use of additional capital to complete the business acquisition and to further

electronically streamline the booking, invoicing and tracking processes.

• Attractive 10 percent per annum participating Redeemable Cumulative Converting Preference

Shares for up to 30 percent ownership in the Company for A$750,000.00 with Board

representation available to major investors.

• Experienced founder and other employees across Australia, well placed to deliver the growth

strategies in selected categories of goods and customers, remote and other route

expansions, and acquisitions of other synergistic operations.

• Industry competitive edge using proven strategies, flexible responses, innovative ideas and

safe work procedures to meet the needs of customers and emerging market demands.

Hannan Logistics Pty Ltd

Logistics

1991

Expansion

Queensland (head office)

Expansion Capital & Development Partners

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

Colin R Hannan - Executive ChairmanOver 40 years industry experience in interstate contai-nerised removals and transport logistics. Col has made the Hannan name recognisable as a leading service provider in the Australian logistics industry.

Donna M Hannan – Proposed directorInvolved with the business since inception, experienced in home renovation, art, design and fashion.

Bryan D Weir – Proposed directorFormer Chairman of Wridgways Australia Limited. A Director of Walker Douglas & Company, a private investment and advisory group. Mr Weir was also formerly a partner of Freehill, Hollingdale & Page and a Director of Macquarie Corporate Finance Limited.

Corporate StructureProprietary Limited Company with Ordinary Shares held by the founders and the Redeemable Cumulative Converting Preference Shares referred to above held by investors. A Notional Profit and Capital Growth Par-ticipation Scheme operates for the benefit of selected employees.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Hannan Logistics.

28

Executive SummarySince opening the initial public offer (IPO) for Flinders Exploration Limited (FEX) in October 2010

the phosphate and diamond asset base of the Company has been strengthened by continued

exploration. This has upgraded our existing Copper Claim prospect in SA to prefeasibility study

status. The Company has also gained the right to acquire two new gold projects; the Black Cat

gold development project near Coolgardie in WA and the Porters Mount gold exploration project

in the central Lachlan area of NSW.

Current Projects• Copper Claim is located in the southern Flinders Ranges, and has potential for an oxide body

of 10 to 20 million tonnes at a grade of 0.25% to 0.35% copper and contains an Inferred

Mineral Resource of 22 million tonnes at an average grade of 0.25% copper. On listing the

Company will commence a prefeasibility study into developing the project.

• Black Cat has the potential for near term development of a JORC-compliant gold resource

(317,000 tonnes at 2.1 g/t Au). FEX has carried out a scoping study from which gave a

positive result.

• Porters Mount is located in the major copper-gold province of central New South Wales and

has the potential for discovery of a large porphyry copper-gold body.

• FMS JV: FEX’s assets lie in the JV Agreement with FMS which is subject to the successful

raising of capital and listing. FEX can acquire a 51% interest by spending $3.5 million in

two years and a total 75% interest by spending a total $6.0 million on exploration within a

total three years. The JV contains a substantial tenement package which is prospective for

phosphate, diamonds, copper and gold.

• Further Details: FEX is seeking to raise $5,000,000 by the offer of 25,000,000 shares at a

price of 20 cents per share and will accept oversubscriptions of a further $2,000,000.

Key Investment Highlights• Objective: to achieve sustainable production ASAP

• Copper Claim: Prefeasibility study, including drilling and column leach tests, mining lease

application.

• Black Cat: Prefeasibility study, pit optimisations, extension drilling, mine design – followed by

contract mining, ore haulage and toll treatment and production

• Porters Mount: Deep drilling at 200-500 metres depth searching for a world class target

• Diamonds and Phosphate: Bulk sampling and drilling leading to follow up work.

MINING

Board & Management:

Andrew Andrejewskis – ChairmanAndrew brings 43 years of experience in senior roles in the resources industry and government.

David Tucker - Managing DirectorDavid is a minerals geophysicist and has more than 37 years experience in the minerals exploration industry.

Kevin Wills - Executive DirectorKevin has 36 years experience and was the former Managing Director of Flinders Mines.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Flinders Exploration.

Flinders Exploration

Mining

2009

IPO

Adelaide, SA

IPO Capital

Company Name

Sector

Year Established

Business Stage

Location

Seeking

29

Company Updates

Capital raising on trackEastern Harmony New Zealand is pleased to announce that it has secured

over 75% of its $4m target capital raising. With less than $1m to raise, the

company says it is confident of closing this before Christmas, according

to CEO Edward Stauber. Eastern Harmony New Zealand will consider smaller

investment from interested parties ($50,000 - $100,000) which should make

this offering attractive to a wider range of investors.

“White death” gets makeover as low sugar health food Sugar cane fibre developer KFSU says that cane is being heralded as an

unlikely health food of the future after a small processing plant in north

Queensland has discovered a way to turn cane stalks into low-sugar, high-

fibre, gluten-free flour. The cane flour, made from mashed cane stalks with

the sugar juice removed offers northern Australia’s 6000 canegrowers the

prospect of an alternative market for their produce.

BlackWall on the ASX BlackWall Property Funds returns to the Australian Securities Exchange,

rebranded and refreshed after its parent, Pelorus Property Group, demurred

and delisted last year. The property fund manager listed in October under the

code BWF, with $13.6 million in market capitalisation on debut and a register

of 1600 shareholders.

BioPower awarded $5 million grant from Victorian Government The funds will be used as part of the $14 million 250 kW demonstration

plant the company is planning at a grid connected site near Port Fairy.

BioPower has developed its own energy capture technology, which has

been tested at its full scale factory at Mascot in Sydney. The technology

uses “biomimicry” – replicating the motion of large sea plants under wave

conditions. “In developing the bioWAVE technology we set out to address the

many issues that have bedeviled most wave energy technologies,” said Dr

Timothy Finnigan, BioPower chief executive.

30

Company Updates

Photonz scales up manufacturingPhotonz has achieved a major milestone on the path to commercially

manufacturing, by fermentation, the high-value omega-3 fatty acid,

eicosapentaenoic acid (EPA). It has successfully transferred its strain

and fermentation process, developed in Auckland, to a contract facility in

Canada, which has then used that process to ferment material from algal

biomass in a 7.5 tonne industrial scale reactor. This demonstrates the

feasibility of commercial production of EPA from marine microalgae

Barefoot Power wins two awards Barefoot Power is celebrating after winning the Katerva Award for Energy

& Power and the Australian Sustainability Award for Sustainable Small

Company of the Year.

These awards cement Barefoot Power’s status as a leader in sustainability.

Barefoot Power is a global, social for-profit enterprise that manufactures

and distributes solar phone charging and lighting products and business

development services to people at the base of the global economic pyramid.

Upcoming Events

Sydney, Australia

Australia - US Investment Conference

Asian Financial Forum - Australian Mission 2012Hong Kong12 January, 2012 15-19 January, 2012

This conference at the Hyatt Regency, Central Plaza Los Angeles, will allow

Australian companies, both public and private, to present their story to a US

audience mostly comprised of institutional investors, creating opportunities

for Australian Companies in the US market. Representative sectors include:

Resources/Agribusiness, Technology (Biotech, Cleantech + Digital Media),

Financial Services and Diversified Industrials. Companies will be showcased

through a combination of company presentations, Q&A sessions, and one-on-

one meetings, providing investors with an in-depth perspective on investment

opportunities present in these companies today.

For more information or to register for this event go to www.wholesaleinvestor.com.au

Join us in Hong Kong in January 2012 to meet, network and mix with some

of the most influential players in the global financial services industry,

particularly those with an interest in the dynamic markets of the Asia-Pacific

region.

For more information contact Jennifer Catterson at jennifercatterson@thinkglobal.com.au

31

Company Name Code Business Stage Sector

Listing Index

Biotech

Biotech

Renewable Energy

Finance

Property

Finance

Healthcare

FMCG

Cleantech

Renewable Energy

IT/ Finance

Technology/Internet

Mining

Property

Biotecg

Logistics

Superannuation

Biotech

Biotech

Telco/Financial Services

Finance

Biotech

Benitec Biopharma

BioDiem Ltd

BioPower Ltd

Bizpanel Ltd

BlackWall Funds

Bullion Capital

Cynergy Health

Eastern Harmony NZ

EcoQuest Ltd

Elemental Energy

Equiome

Exa Web Solutions

Flinders Exploration

Folkestone

Global Kinetics

Hannan Logistics

Investment Administration

Jubilent Health

Mesynthes Ltd

Mint Wireless

TRAC Financial

Xenexus Pharmaceuticals

BLT

BDM

BPL

BZP

BWF

BUL

CLG

EHNZ

ECQ

EET

ECQ

EWS

FEX

FLK

GKC

HNL

IVA

JHA

MSY

MNW

TFF

XNP

Early

Commercialisation

Growth

Operational

IPO

Expansion

Development

Commercialisation

Trading

Commercialisation

Commercialisation

Expansion

IPO

ASX listed

Commercialisation

Expansion

Early

Market ready

Early Stage

Early

Expansion

Early

Further InformationFor information on these and other opportunities, go to www.wholesaleinvestor.com.au

How cangrowing abusiness make you feel like an emperor?

When our Private Clients teamspoke with brothers Emanuel andNapoleon Perdis, of Napoleon PerdisCosmetics, they had outgrown theirlocal advisor and were looking toexpand. Emanuel wanted someonewho could work with them onexpansion plans and refinancing,but more importantly, he neededa trusted business advisor hecould come to for future decision-making. Their unique take on thecosmetics industry – that they’renot in the fashion business, but theconfidence boosting business – hasseen them grow and grow. With thecontinued advice of their PrivateClients team, they are now on theirway to becoming one of the mostrecognised cosmetics brandsfrom Australia to Hollywood.And Emanuel, he loves the fact thatalthough he’s not our only client,he certainly feels like he is.

What would you like to grow?Share your story at whatwouldyouliketogrow.com.au